智通财经APP获悉，复锐医疗科技(01696)盘中涨超10%，截至发稿，涨6.45%，报5.28港元，成交额1076万港元。
消息面上，复锐医疗科技发布年度财报，收益3.49亿美元，同比下降2.8%。其中，直销营收3.04 亿美元占营收87%，营收占比同比上升9pct。公司纯利2513万美元，同比下滑20.2%，每股盈利5.36美仙。末期息派12.6港仙，公司总股本4.7亿股，共分红0.55亿元，分红比例达30%。
方正证券指出，公司短期业绩受渠道变革过渡期及利率波动等外部环境扰动，预计随着美国订单环比改善、肉毒产品获批及能量源新品放量有望迎来经营端的改善，长期仍看好能量源龙头增长及直销渠道拓展，肉毒Daxxify与透明质酸Profhilo预计25年上市，因此25年将成为公司注射业务拓展的拐点，有望拓宽公司业务边界贡献显著增量。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.